What would you do if your brand could no longer advertise on TV?

For thirty years, the loudest brand won. That era is ending, and the disruption everyone fears is the best opening the underdogs have had in a generation.

Years ago, during annual brand planning while working in pharma and leading a COE, an executive asked a question I’ve never forgotten: without changing the revenue goals and spend, how would this brand survive the elimination of DTC advertising in general or TV only?

It was a thought experiment with low odds, and that was the point. It attacked what we all took as a given: that you buy reach to drive revenue at scale, and that the biggest reach channel was just part of the furniture. Take it away, keep the number, and every comfortable assumption is back on the table. I found it intriguing then. It is no longer hypothetical now.

For almost thirty years, pharma marketing ran on a simple, unfair rule: the brand with the biggest broadcast budget won the patient. If you couldn’t afford a Super Bowl spot, you weren’t really in the conversation. That rule is cracking. If you run a smaller or emerging brand, you should be the first to cheer.

What’s breaking

The US is one of only two countries that allow DTC prescription advertising,^[1] and more than $10.1 billion a year flows into it.^[2] The entire 60-second TV spot rests on one mechanism: broadcast ads state only the major risks aloud and point you elsewhere for the rest. That trade-off, in place since the late 1990s, is why drug ads are watchable.

In September 2025, FDA and HHS moved to take it away.^[3] By the agencies’ own admission, a spot reading every contraindication would run minutes, not seconds. Before this mechanism existed, broadcast drug ads were rare for exactly that reason. This is not a tweak. It is a question of whether the format survives.

And it is two fronts, not one. In Congress, the Responsibility in Drug Advertising Act would bar DTC for a new drug’s first three years on the market.^[4] Both efforts face First Amendment headwinds and may not pass. But the intent is clear, and intent is what you plan against: HHS now blames DTC for roughly 31% of the rise in drug spending since 1997.^[5]

So here is the provocative part. The most exposed brands aren’t the small ones. They’re the giants: the blockbuster franchises with hundreds of millions in TV spend, the most inertia to unwind, and agencies built around a channel going dark. Their megaphone is breaking.

The void won’t be filled by better TV

Every brand reaches for the nearest substitute: connected TV, streaming, social, influencer. Most miss the point. The same 2025 action named “closing digital loopholes” and social media oversight.^[6] CTV gives sharper targeting but inherits the disclosure burden breaking broadcast.

Short-form is the real trap. A Reel, a TikTok, a YouTube Short is built for seconds, sound on, thumb already moving. You cannot fit a major-risk statement into fifteen vertical seconds without killing the thing that makes it work. The format that looks most like cheap scale is the one you can least use for a branded claim. Branded social is not the escape hatch. It is the next room the squeeze walks into.

Where social earns its place is the one job that doesn’t trip the rules: unbranded education. Disease awareness, patient community, help-seeking content that never pairs a drug name with a claim carries no fair-balance burden, because it isn’t a drug ad. Use social to build demand you can actually capture. Don’t ask it to make the claim TV used to make for you.

But can the math still work?

The question your CFO asks first. Look at Vertex. Its cystic fibrosis franchise drove $11.02 billion in 2024, with Trikafta alone at $8.9 billion the year before, on essentially no consumer TV.^[7] The CF population is small and identifiable. When a label expansion adds a few hundred eligible patients, you don’t buy a Super Bowl to find them. You reach them through specialists, advocacy, and patient support. Precision, not reach.

So the honest answer is another question: how findable is your patient? The more identifiable they are, the easier broadcast is to replace and the better your return without it. That names the seam in my own headline: yes, the three-year rule targets new launches, and emerging brands are new launches. But a brand whose patient is findable never needed the broadcast launch the rule takes away.

Now what

The rulemaking will take a year or more, with comment periods and a constitutional fight. That is not a reason to wait. It is your opportunity. Build first-party data, stand up unbranded education, deepen point of care, and fix your measurement: the no-regrets moves that pay off however the rule lands. The brand that can’t measure impact will panic when broadcast wobbles. The one that can will arbitrage the disruption while the giants are still in meetings.

For thirty years the rule favored the big. The new one favors the brand closest to the patient, that owns its relationships, and won’t confuse being loud with being effective. That was never the giants. It was always you.

The brands that map their options are the ones still standing when the changes happen. Want to pressure test your thinking? Contact Kairos Meridian today.

---

^[1]The United States and New Zealand are the only two countries that permit direct-to-consumer prescription drug advertising. (HHS/FDA, 2025.)

^[2]US direct-to-consumer prescription drug spending exceeded $10.1 billion in 2024, with several billion of that in national TV. (eMarketer / iSpot.tv, 2024–2025.)

^[3]On September 9, 2025, HHS and FDA announced rulemaking to rescind the “adequate provision” mechanism (21 CFR 202.1) that lets broadcast ads carry only a major-risk statement while directing viewers elsewhere for full safety information, alongside roughly 100 cease-and-desist letters and thousands of warning letters. (HHS/FDA, September 9, 2025.)

^[4]The Responsibility in Drug Advertising Act (Sen. Angus King and Rep. Rosa DeLauro) would prohibit DTC advertising of a new drug for the first three years after FDA approval, with the FDA able to waive the third year if an affirmative value to public health is established. Reintroduced February 2025. A separate, broader bill (the End Prescription Drug Ads Now Act, S. 2068) would ban DTC across all media. (Office of Sen. Angus King; S. 2068, 119th Cong., 2025.)

^[5]HHS attributes roughly 31% of the rise in US drug spending since 1997 to DTC advertising; the figure is an HHS estimate and is contested by industry. Congressional Budget Office analysis separately links a 10% increase in DTC advertising to a 1–2.3% increase in prescription drug spending. (HHS; CBO, 2025.)

^[6]The September 2025 HHS/FDA initiative also stated an intent to “close digital loopholes” by expanding regulatory oversight to social media promotional activity, even as social became the fastest-growing slice of DTC spending. (HHS/FDA; industry analysis, 2025.)

^[7]Vertex Pharmaceuticals reported full-year 2024 product revenue of $11.02 billion, driven by its cystic fibrosis franchise; Trikafta alone generated approximately $8.9 billion in 2023. Vertex markets to a small, identifiable patient population through specialists, care centers, and patient support rather than consumer broadcast advertising. (Vertex Pharmaceuticals financial results, 2024–2025.)